WTA
AZN icon

Washington Trust Advisors’s AstraZeneca AZN Stock Holding History

Washington Trust Advisors’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-45
Closed -$8.27K – 690
2025
Q4 		$8.27K Sell
45
-10
-18% -$1.75K ﹤0.01% 518
2025
Q3 		$8.36K Hold
55
– – ﹤0.01% 549
2025
Q2 		$7.62K Hold
55
– – ﹤0.01% 514
2025
Q1 		$8.01K Hold
55
– – ﹤0.01% 498
2024
Q4 		$7.14K Buy
55
+9
+20% +$1.26K ﹤0.01% 524
2024
Q3 		$7.09K Sell
46
-134
-74% -$21.6K ﹤0.01% 528
2024
Q2 		$28K Buy
180
+139
+339% +$20.9K ﹤0.01% 373
2024
Q1 		$5.49K Hold
41
– – ﹤0.01% 560
2023
Q4 		$5.46K Buy
+41
New +$5.33K ﹤0.01% 561
2023
Q2 		– Sell
-197
Closed -$27.3K – 673
2023
Q1 		$27.3K Sell
197
-173
-47% -$23.3K ﹤0.01% 378
2022
Q4 		$50.2K Sell
370
-556
-60% -$69.7K 0.01% 310
2022
Q3 		$102K Buy
926
+646
+231% +$82K 0.01% 275
2022
Q2 		$37K Sell
280
-479
-63% -$62.9K ﹤0.01% 442
2022
Q1 		$101K Sell
759
-125
-14% -$15K 0.01% 331
2021
Q4 		$103K Buy
+884
New +$104K 0.01% 357

Other funds holding AZN

IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VAM
Vanguard Asset Management London, Ec4n 8af $117B AUM

Washington Trust Advisors's AZN Position: Q1 2026 in Review

Washington Trust Advisors sold out of AstraZeneca (AZN) in Q1 2026, closing a stake of 45 shares — an estimated $8.27K sold.

Washington Trust Advisors first reported a position in AZN in Q4 2021 and held it in 15 quarters. The position peaked at $103K in Q4 2021. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • Washington Trust Advisors reported no remaining AstraZeneca position as of Q1 2026 after selling out during the quarter.
  • Washington Trust Advisors sold 45 AstraZeneca shares in Q1 2026, an estimated $8.27K.
  • Washington Trust Advisors first reported a position in AstraZeneca in Q4 2021 and held it in 15 quarters.
  • Washington Trust Advisors's AstraZeneca position peaked at $103K in Q4 2021.
  • 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Washington Trust Advisors's 13F filing for Q1 2026, filed 6 Apr 2026.